Preservation of Renal Function during Gout Treatment with Febuxostat: A Quantitative Study

References

• . Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Takishita S. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res. 2001;24(6):691–697
   PubMed Web of Science ®Google Scholar
• . Kang DH, Nakagawa T. Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease. Semin Nephrol. 2005;25(1):43–49
   PubMedGoogle Scholar
• . Sonoda H, Takase H, Dohi Y, Kimura G. Uric acid levels predict future development of chronic kidney disease. Am J Nephrol. 2011;33(4):352–357
   PubMedGoogle Scholar
• . Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med. 2009;169(4):342–350
   PubMed Web of Science ®Google Scholar
• . Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R. Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008;19(12):2407–2413
   PubMed Web of Science ®Google Scholar
• . Zhu Y. Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63(10):3136–3141
   PubMed Web of Science ®Google Scholar
• . Zhu Y. Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population. Am J Med. 2012;125(7):679–687. e671
   PubMed Web of Science ®Google Scholar
• . Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol. 1976;31(2):155–163
   PubMedGoogle Scholar
• . Kuo CF, Luo SF, See LC, . Hyperuricaemia and accelerated reduction in renal function. Scand J Rheumatol. 2011;40(2):116–121
   PubMed Web of Science ®Google Scholar
• . Uloric® [package insert]. Deerfield, IL: Takeda Pharmaceuticals North America Inc; 2011
   Google Scholar
• . Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana L. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol. 2011;17(1):7–13
   PubMed Web of Science ®Google Scholar
• . Halpern R, Mody RR, Fuldeore MJ, Patel PA, Mikuls TR. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. Curr Med Res Opin. 2009;25(7):1711–1719
   PubMed Web of Science ®Google Scholar
• . Becker MA, Schumacher HR, Espinoza LR, . The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63
   PubMed Web of Science ®Google Scholar
• . Becker MA, Schumacher HR Jr, Wortmann RL, . Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450–2461
   PubMed Web of Science ®Google Scholar
• . Schumacher HR Jr, Becker MA, Wortmann RL, . Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540–1548
   PubMed Web of Science ®Google Scholar
• . Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful long-term urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273–1282
   PubMed Web of Science ®Google Scholar
• . Levey AS, Coresh J, Balk E, ; National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139(2):137–147
   PubMed Web of Science ®Google Scholar
• . Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41
   PubMed Web of Science ®Google Scholar
• . Levey AS, Stevens LA, Schmid CH, . A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612
   PubMed Web of Science ®Google Scholar
• . Ben—Dov IZ, Kark JD. Serum uric acid is a GFR-independent long-term predictor of acute and chronic renal insufficiency: the Jerusalem Lipid Research Clinic cohort study. Nephrol Dial Transplant. 2011;26(8):2558–2566
   PubMedGoogle Scholar
• . Bellomo G, Venanzi S, Verdura C, Saronio P, Esposito A, Timio M. Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis. 2010;56(2):264–272
   PubMed Web of Science ®Google Scholar
• . Schumacher HR Jr, Becker MA, Lloyd E, MacDonald PALademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009;48(2):188–194
   PubMed Web of Science ®Google Scholar
• . Goicoechea M, de Vinuesa SG, Verfalles U, . Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5(8):1388–1393
   PubMed Web of Science ®Google Scholar
• . Malik UZ, Hundley NJ, Romero G, . Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production. Free Radic Biol Med. 2011;51(1):179–184
   PubMed Web of Science ®Google Scholar
• . Neogi T, George J, Rekhraj S, Struthers AD, Choi H, Terkeltaub RA. Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal. Arthritis Rheum. 2012;64(2):327–338
   PubMedGoogle Scholar
• . Jones DP, Richey PA, Alpert BS, Li R. Serum uric acid and ambulatory blood pressure in children with primary hypertension. Pediatr Res. 2008;64(5):556–561
   PubMedGoogle Scholar
• . Perlstein TS, Gumieniak O, Williams GH, . Uric acid and the development of hypertension: the normative aging study. Hypertension. 2006;48(6):1031–1036
   PubMed Web of Science ®Google Scholar
• . Sundstrom J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension. 2005;45(1):28–33
   PubMed Web of Science ®Google Scholar
• . Loeffler LF, Navas—Acien A, Brady TM, Miller ER 3rd, Fadrowski JJ. Uric acid level and elevated blood pressure in US adolescents: National Health and Nutrition Examination Survey, 1999–2006. Hypertension. 2012;59(4):811–817
   PubMed Web of Science ®Google Scholar
• . Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300(8):924–932
   PubMed Web of Science ®Google Scholar
• . Kanbay M, Huddam B, Azak A, . A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol. 2011;6(8):1887–1894
   PubMed Web of Science ®Google Scholar
• . Kanbay M, Ozkara A, Selcoki Y, . Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007;39(4):1227–1233
   PubMedGoogle Scholar
• . Krishnamurthy A, Lazaro DM, Blumenthal DR, Gerber DA, Flom PL. The effect of allopurinol on renal function in patients with hyperuricemia: a case-control study. Arthritis Rheum. 2010;62( 10 suppl):S68
   Google Scholar
• . Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47(1):51–59
   PubMed Web of Science ®Google Scholar
• . Talaat KM, el—Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol. 2007;27(5):435–440
   PubMed Web of Science ®Google Scholar
• . Choi HK, Soriano LC, Zhang Y, Rodriguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ. 2012;344:d8190
   PubMed Web of Science ®Google Scholar
• . Hamburger M, Baraf HS, Adamson TC 3rd, ; European League Against Rheumatism. 2011 Recommendations for the diagnosis and management of gout and hyperuricemia. Postgrad Med. 2011;123(6 suppl l):3–36
   PubMedGoogle Scholar
• . Khanna D, Fitzgerald JD, Khanna PP, ; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431–1446
   PubMed Web of Science ®Google Scholar